HARBIN, China, April 29 /PRNewswire-Asia/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced the Company plans to launch Qing Re Jie Du Oral Liquid ("Qing"), a traditional Over-the-Counter ("OTC") Chinese Medicine for the treatment of influenza ("the flu") and upper respiratory infections in June 2010.
Qing is an all-natural, plant-based traditional OTC Chinese Medicine with proven benefits in treating the flu, upper respiratory infections, and sore throats. The Company expects Qing to generate $1.0 million to $1.5 million in revenues in fiscal 2010.
"We have great confidence in the performance and effectiveness of our latest product, Qing Re Jie Du Oral Liquid, and anticipate positive market acceptance," said Mr. Shaoming Li, the Chairman and CEO of Renhuang. "Qing's all-natural active ingredients are effective against flu symptoms and cause no side effects associated with chemical drugs. At Renhuang, we are committed to developing superior products which meet the needs of our customers and we are equally committed to creating value for our shareholders. In this pursuit, we continue to expand our product portfolio to boost our revenue stream and fuel Renhuang's growth."
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three
GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com
Safe Harbor Statement
This press release contains certain statements that may include
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to achieve its revenue and growth forecast for Qing Re Jie Du Oral Liquid, the Company's ability to achieve its financial guidance, ability to continue to improve its days sales outstanding, ability to list its shares on a senior stock exchange, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
Company Contact:
Renhuang Pharmaceuticals, Inc.
Ms. Portia Tan, IR Contact
Tel: +86-451-5392-5461
Email: ir@renhuang.com
CCG Investor Relations:
Ms. Lei Huang, Account Manager
Tel: +1-646-833-3417 (New York)
Email: lei.huang@ccgir.com
Web: www.ccgirasia.com
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
